Immune cell therapy in patients with relapsed or resistant B-A

Phase 1

Recruiting

Conditions: relapsed or incurable B Cell Acute Lymphoblastic Leukemia.
Acute lymphoblastic leukemia, in relapse
C91.02

Registration Number: IRCT20200413047063N5

Lead Sponsor: Omid cell and tissue processing company

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 10

Inclusion Criteria

Eligible diseases: Acute lymphocytic leukemia (ALL CD19+).
Patients 3 years of age or older, and must have a life expectancy > 12 weeks.
Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than 60.
Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR NK cells.
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: White blood cell count (WBC) = 2500c/ml, Platelets = 50×10^9/L, Hb = 9.0g/dL, lymphocyte (LY) = 0.7×10^9/L, LY% = 15%, Alb = 2.8g/dL, serum lipase and amylase < 1.5×upper limit of normal, serum creatinine = 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 5×upper limit of normal, serum total bilirubin = 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
Ability to give informed consent.

Exclusion Criteria

Pregnant or nursing women may not participate.
Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time of screening.
Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
History of severe immediate hypersensitivity to any of the agents including cyclophosphamide, fludarabine, or aldesleukin.
Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
The existence of unstable or active ulcers or gastrointestinal bleeding.
Patients need anticoagulant therapy (such as warfarin or heparin).
Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
Patients using fludarabine or cladribine chemotherapy within 3 months prior to leukapheresis.